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Abstract
Objective Increasing evidence supports the role of central sensitisation in osteoarthritis (OA) pain. In this study, we used 
neuroimaging to compare pain-processing regions of the brain in participants with and without hand OA. We then assessed 
for volumetric changes in these brain regions following treatment with centrally acting analgesics.
Methods Participants with hand OA (n = 28) underwent T1-weighted MRI of the brain before and after 12 weeks of treat-
ment with pregabalin, duloxetine or placebo. Grey matter volume in the anterior cingulate cortex (ACC), insular cortex and 
thalamus was compared to non-OA control subjects (n = 11) using FreeSurfer regional volumetric analysis and voxel-based 
morphometry, and evaluated for differences pre- and post-treatment.
Results Relative to non-OA controls, hand OA participants had areas of reduced grey matter volume in the ACC at baseline 
(p = 0.007). Regional volumetric differences in the ACC persisted after 13 weeks’ treatment with pregabalin or duloxetine 
(p = 0.004) with no significant differences between treatment cohorts, despite improvements in NRS pain scores for prega-
balin (p = 0.005) and duloxetine (p = 0.050). The ACC grey matter changes persisted despite a significant improvement in 
pain in the pregabalin and duloxetine groups vs. placebo. No structural differences were observed in the insular cortex or 
thalamus at baseline or following treatment.
Conclusion Our study found evidence of reduced ACC grey matter volume in participants with hand arthritis that persisted 
after treatment with centrally acting analgesics pregabalin and duloxetine, respectively. The sustained changes observed in 
the ACC in our study could reflect the relatively short duration of treatment, or that the differences observed are irreversible 
volume changes due to chronic pain that are established over time.
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Introduction
Osteoarthritis (OA) of the hand is a major cause of pain 
and functional impairment worldwide, with many people 
experiencing chronic pain despite treatment with paraceta-
mol, non-steroidal anti-inflammatory drugs (NSAIDs) and 
opioids. An increasing number of studies implicate abnor-
malities in brain regions associated with pain processing 
in the maintenance of chronic pain in OA and other condi-
tions [1–3]. Using functional MRI, it has been shown that 
pain-processing areas of the brain, including the cingulate 
cortices, insular cortices and thalamus, are activated in hand 
OA patients but not control subjects during a finger-flexion 
task [4]. Grey matter volumetric changes have also been 
demonstrated in pain-processing brain regions in patients 
with hip and knee OA and other chronic pain conditions, 
with the pattern of brain involvement varying according to 
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the underlying condition [1, 5–9]. Amelioration of hip OA 
pain through arthroplasty increased thalamic grey matter 
volume in one study [5], and increased anterior cingulate 
cortex (ACC) and insular cortex grey matter volume in 
another study [6]. These findings suggest that there can be 
neuroplasticity, rather than purely neurodegenerative effects, 
involved in chronic pain. They also provide a rationale for 
the investigation of centrally acting analgesic agents as 
treatment options for chronic OA pain; supported by stud-
ies demonstrating pain improvements following treatment 
with pregabalin and duloxetine [10–12].
We hypothesised that structural differences in the ACC, 
insular cortex and thalamus would be present between hand 
OA participants and non-OA control participants, and that 
treatment with centrally acting analgesics would lead to vol-
umetric changes in these brain regions. To investigate this 
hypothesis, we obtained volumetric brain MRI from hand 
OA participants before and after treatment with pregabalin, 
duloxetine or placebo, and compared regional brain volumes 
with non-OA control participants.
Methods
This brain neuroimaging work was part of a randomised, 
double-blinded, placebo-controlled study, designed to assess 
the effects of pregabalin and duloxetine on pain outcomes. 
The clinical endpoints of this study, in addition to the full 
trial protocols, have been reported elsewhere [10, 11]. All 
trial protocols were approved by the study sponsor and the 
MHRA (Medicines and Healthcare products Regulatory 
Agency), UK. All procedures performed in studies involv-
ing human participants were in accordance with the ethi-
cal standards of the institutional and/or national research 
committee and with the 1964 Helsinki Declaration and its 
later amendments or comparable ethical standards. Ethical 
approval for this study was provided by the London-Sur-
rey Borders Ethics Committee, with approval number 12/
LO/0047. Informed consent was obtained from all individual 
participants included in this study.
Clinical Trial Registration Number: NCT02612233.
The trial protocol was followed as published, according 
to CONSORT guidelines and inclusion–exclusion criteria.
Participants
Study participants were recruited from primary care and 
rheumatology outpatient clinics in London, UK. Participants 
were eligible for inclusion if they were aged 40–75 years, 
had hand OA diagnosed by American College of Rheumatol-
ogy criteria, with pain of at least five or above on a Numeri-
cal Rating Scale (NRS) of 0–10. Participants were receiving 
usual standard of care for hand OA, including paracetamol 
and/or NSAIDs. Exclusion criteria were the presence of 
other rheumatological diagnoses; contraindications to, or 
previous use of, duloxetine or pregabalin; concurrent use of 
opioids; current or planned pregnancy; uncontrolled depres-
sion; recent surgery; ischaemic heart disease; diabetes melli-
tus; excessive alcohol intake; chronic kidney disease; hepatic 
impairment and hypertension. Volunteers with no evidence 
of symptoms of hand OA were recruited, 11 of whom were 
selected as neuroimaging control subjects for this study on 
the basis of having similar mean ages and age ranges to the 
hand OA participants. The control subjects did not report 
any pain, anxiety or depression.
Study groups
Participants with hand OA were randomised to receive one 
of three study treatments: pregabalin, duloxetine or pla-
cebo. Before the treatment, all groups were homogeneous 
for pain reporting measures, concomitant medication use 
and duration of diagnosis, as previously published [10]. All 
three treatments were administered using a dose escalation/
de-escalation protocol over a period of 12 weeks: week 1: 
pregabalin, 150 mg once nightly (ON), vs. duloxetine, 30 mg 
ON, vs. placebo, 1 capsule ON; weeks 2–11: pregabalin, 
300 mg ON, vs. duloxetine, 60 mg ON, vs. placebo, 2 cap-
sules ON; week 12: pregabalin, 150 mg ON, vs. duloxetine, 
30 mg ON, vs. placebo, 1 capsule ON; followed by ces-
sation of therapy. Neuroimaging control subjects were not 
administered any treatment. Study drugs were supplied by 
Sharp Clinical Services (formerly Bilcare GCS (Europe), 
Powys, UK), which over-encapsulated pregabalin 150 mg 
tablets or duloxetine 30 mg tablets and produced visually 
identical placebo capsules. The random allocation sequence, 
with a block size of nine, was generated by the manufacturer 
and implemented through sequentially numbered containers. 
Neither participants nor investigators were aware of treat-
ment assignment until after completion of the trial, which 
was performed after the last patient and last visit was con-
ducted at the end of the trial. Ongoing use of paracetamol 
and/or NSAIDs was permitted during the study period. Our 
sample size was based on the IMMPACT guidelines [11] 
for randomised controlled trials using the validated 0–10 
point pain numerical rating scale (NRS) for the sample size 
calculation and primary outcome measures, and is reported 
in our published paper [10].
Participants enrolled into the main clinical study 
described above [10] were subsequently assessed for MRI 
eligibility using a standard clinical safety checklist. Partici-
pants were ineligible for MRI if they had a cardiac pace-
maker, pacing wires, artificial heart valve, previous brain 
haemorrhage with clipping or coil insertion, hydrocepha-
lus shunt, history of work with high-speed metal machin-
ing tools, recent joint replacement or other contraindicated 
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implants, e.g. cochlear implants. Repeat neuroimaging was 
performed on hand OA participants at 13 weeks, after com-
pletion of study treatment. Neuroimaging control subjects 
did not receive study treatment and were not re-imaged at 
13 weeks.
Procedures
The primary endpoints were the numerical rating scale 
(NRS) and the Australian and Canadian Hand Osteoarthritis 
Index (AUSCAN) rating scale for pain after 13 weeks’ treat-
ment, which has been reported in the clinical trial outcome 
data elsewhere [10]. NRS and AUSCAN pain measures, as 
well as HADS anxiety and depression scores, were recorded 
at baseline and after 13 weeks’ intervention for all OA study 
participants.
High-resolution 3D T1-weighted images were acquired at 
baseline from all eligible hand OA and non-OA participants 
and also after treatment at the 13-week time point for par-
ticipants with OA. Images were obtained with a 3T Philips 
Dual Tx Achieva using a 32-channel head coil and a 3D 
Turbo Field Echo with parameters: TE = 4 ms; TR = 8 ms; 
flip angle = 8°; a pre-inversion pulse; echo train length = 240; 
a 240 mm field-of-view in the sagittal orientation with 
1 mm in-plane resolution and a 160 mm field of view in the 
left–right direction with 107 slices of 1.5 mm thickness. A 
sensitivity encoding (SENSE) factor of 2.0 and 0.75 k-space 
sampling factor resulted in a 3.8 min total acquisition time.
Regional volumetric analysis
Tissue volumes of a priori regions of interest (ROI) were 
obtained using FreeSurfer version 5.3 [13] and statistical 
comparisons made with SPSS version 22 (IBM Corp). The 
ACC (with separate caudal and rostral regions in Free-
Surfer), insular cortex and thalamus of each hemisphere 
were delineated for each participant using the inbuilt 
DKTAtlas40 cortical and Aseg subcortical atlases.
Voxel‑based morphometry
Voxel-based morphometry (VBM) was performed using 
SPM12 to detect significant localised changes in tis-
sue volume within the a priori ROIs [14]. Pre-processing 
steps included segmentation into grey matter, white matter 
and cerebrospinal fluid using SPM. The native grey mat-
ter images were skull stripped and spatially normalised to 
Montreal Neurological Institute (MNI) space using a study-
specific template. These images were Jacobian-scaled and 
smoothed with an isotropic Gaussian kernel of 6 mm full 
width at half maximum. Image masks were created for the 
a priori ROIs (ACC, insular cortex and thalamus of each 
hemisphere) using the WFU PickAtlas toolbox (http://fmri.
wfubm c.edu/).
Statistical analysis
The IBM SPSS Statistics 25 package was used for all statisti-
cal analysis apart from that which was implicit to the volu-
metric analyses of the MRI data as described above. Analy-
sis of clinical and MRI parameters was performed on the 
patient subgroup from the main clinical trial [10] for which 
there were both pre and post-treatment MRI scans, and in 
comparison to an age-matched group of healthy controls 
who had an MRI scan with no subsequent treatment. A one-
way ANOVA was used to assess whether there were demo-
graphic differences between patient and control groups. An 
ANOVA using a general linear model with repeated meas-
ures across all treatment groups was used to assess whether 
there were treatment related effects of clinical scores or 
brain volumes. A post hoc analysis using paired t tests was 
used to assess whether there were significant differences in 
clinical scores and brain volumes for each treatment group. 
Two-sample t tests were used to assess whether there were 
significant differences in brain volumes between OA patients 
and controls. For the comparison of control and OA patient 
brain volumes, age and total intracranial volume were used 
as necessary covariates.
Regional volumetric statistical analysis
A mixed linear effects model was used to compare vol-
umes between patient and control groups, with age and 
total intracranial volume as covariates. Repeated measures 
ANOVA were used to assess treatment-associated volumet-
ric differences in the a priori ROIs between the pregabalin, 
duloxetine and placebo cohorts. Results were considered 
statistically significant if the two-tailed p values obtained 
were less than 0.05.
Voxel‑based morphometry statistical analysis
Structural comparisons between patients and controls were 
performed with a two-sample t test, covarying for age and 
total intracranial volume. Paired t tests were used for com-
parisons of patients before and after treatment. All voxel-
based statistics were performed in SPM12. Corrections for 
multiple comparisons within the ROIs were performed using 
family-wise error (FWE) at peak level and cluster level. 
Findings are displayed as uncorrected and FWE-corrected, 
two-tailed p values, with thresholds of statistical significance 
set at p < 0.001 and p < 0.05, respectively.
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Results
Study participants and demographics
Thirty-nine participants were recruited from the total of 
65 participants enrolled into the main clinical trial who 
were eligible for and agreed to undergo MRI scanning. 
The full clinical trial results are published [10, 11]. Of the 
39 patients who underwent a baseline MRI, 30 patients 
agreed to have a post-treatment MRI scan. The MRI data 
from two hand OA participants were further excluded due 
to image artefacts, leaving 28 hand OA participants with 
MRI data available for pre- and post-treatment analysis 
and 11 controls in an aged matched group for compara-
tive analysis. Randomisation of hand OA participants into 
treatment cohorts occurred as part of the main clinical 
study, prior to assessment of eligibility for inclusion into 
this MRI sub-study. Differences were, therefore, present 
in the numbers of hand OA participants with MRI data in 
each of the three treatment cohorts: duloxetine (n = 11), 
pregabalin (n = 6), placebo (n = 11). The demographics 
of the hand OA and control groups are shown in Table 1 
and there were no significant differences between control 
and patient groups. In addition, ANOVA across the three 
treatment groups of patients showed no significant dif-
ferences for age, baseline NRS and AUSCAN pain scores 
or HADS anxiety and depression scores (p > 0.2 for all 
measures).
Regional volumetric analysis at baseline
Using FreeSurfer regional volumetric analysis [13], we 
assessed for baseline differences between hand OA and 
control participants in the a priori ROIs (the ACC, insular 
cortices and thalami). Grey matter volume in the right 
hemispheric rostral ACC was 14% lower in hand OA par-
ticipants than control participants at baseline (p = 0.007) 
(Fig. 1). No significant baseline volumetric differences 
were evident in the insular cortices or thalami.
Voxel‑based morphometry at baseline
Voxel-wise comparisons were performed using VBM [14] 
to identify sub-clusters of reduced grey matter within the 
ACC of hand OA subjects at baseline, relative to control 
subjects. In the right hemispheric ACC, a cluster of 270 vox-
els was evident with an uncorrected significance threshold of 
p < 0.001. In the left hemispheric ACC, a cluster of 65 vox-
els was evident with an uncorrected significance threshold 
of p < 0.001 (Fig. 2; see legend for FWE-corrected p values 
and MNI coordinates). No significant volumetric differences 
were evident in the insular cortices or thalami.
Table 1  Demographics of hand 
OA participants and control 
participants used in the MRI 
analysis
Study demographic Hand OA partici-
pants
Control participants p value for dif-
ferences between 
groups
Number of subjects 28 11
Age (years), mean (SD) 62 (7.7) 59 (7.4) 0.18
Women (%) 24 (86) 9 (82) 0.77
Handedness 27 Right
1 Left
11 Right
0 Left
0.54
Fig. 1  Boxplot representation of grey matter volume in the right 
hemispheric rostral anterior cingulate cortex (RH rACC) of control 
subjects (n = 11) and subjects with hand OA (n = 28) undergoing MRI 
at baseline and after completion of study treatment (13 weeks). Rela-
tive to controls, RH rACC grey matter volume was lower in hand OA 
subjects at baseline (p = 0.007) and at 13 weeks (p = 0.004) using a 
mixed effects linear regression model with age and total intracranial 
volume as covariates. Volumes were derived from FreeSurfer regional 
volumetric analysis and have been displayed graphically as normal-
ised to total intracranial volume. Median volumes are displayed in the 
boxplot, along with upper and lower quartiles. Inner fences represent 
1.5 times the interquartile range and circles represent outlier data
Rheumatology International 
1 3
Post‑treatment analyses
The effects of treatment on MRI derived brain volumes and 
clinical scores of pain were assessed with ANOVA using 
a general linear model with repeated measures across all 
treatment groups. Repeated measures ANOVA revealed no 
significant regional volumetric changes between treatment 
cohorts in the ACC, insular cortex or thalamus. Similarly, 
VBM analyses showed no significant treatment-associated 
volumetric changes in the a priori ROIs. Relative to non-OA 
controls, the volumetric differences in the right hemispheric 
rostral ACC of hand OA participants were still evident on 
repeat imaging at 13 weeks, after completion of study treat-
ment (p = 0.004) (Fig. 1).
Repeated measures ANOVA of the pain scores indicated 
p = 0.068 for the treatment response measured using NRS 
and p = 0.021 of that measured by AUSCAN pain. There 
were no significant differences in response between treat-
ments, but the pregabalin-treated cohort showed the greatest 
reduction in pain score (see supplementary Figs. 1 and 2) as 
also observed in the main clinical study [10].
Paired t tests were used post hoc to assess differences 
in clinical pain (see below) and in anxiety and depression 
scores (Supplementary Table). Baseline NRS for pain was 
6.64 in the duloxetine cohort, 5.83 in the pregabalin cohort 
and 6.45 in the placebo cohort. After 12 weeks of treat-
ment, a significant reduction in pain was seen in the prega-
balin cohort (mean NRS pain reduction of 2.83; 95% con-
fidence interval 1.29–4.38; p = 0.005). With duloxetine, a 
reduction in pain of borderline statistical significance was 
noted (mean NRS pain reduction of 1.45; 95% confidence 
interval 0.00–2.91; p = 0.050). No significant change in pain 
was seen with placebo (mean NRS pain reduction of 0.64; 
95% confidence interval − 0.33–1.60; p = 0.171).
Baseline AUSCAN pain was 292 in the duloxetine cohort, 
311 in the pregabalin cohort and 315 in the placebo cohort. 
After 12 weeks of treatment, a significant reduction in pain 
was seen in the pregabalin cohort (mean AUSCAN pain 
reduction of 132; 95% confidence interval 48–217; p = 0.01). 
There were no significant changes in AUSCAN pain for 
duloxetine or placebo (see Supplementary Table).
Hospital Anxiety and Depression Scale (HADS) anxi-
ety and depression scores were not significantly different 
following treatment with pregabalin or duloxetine (see sup-
plementary table). Hand OA participants receiving placebo 
had no change in their HADS depression scores but higher 
HADS anxiety scores following treatment (p = 0.031), albeit 
still below the threshold score for mild anxiety.
Discussion
The data we report in this study are a brain MRI subgroup 
analysis of a clinical trial which compared centrally acting 
analgesics pregabalin and duloxetine to placebo in hand OA. 
In this sub-study, we found the same pattern of treatment 
response as in the main clinical study, with a significant 
reduction in clinical pain scores for those patients treated 
Fig. 2  Voxel-based morphometric analysis demonstrating clusters 
of reduced grey matter volume in the ACC of participants with hand 
OA, relative to control subjects, at baseline. The right side of the fig-
ure represents the right side of the brain. Clusters are indicated on a 
brain template with corresponding slice coordinates and a t test sig-
nificance scale. The right hemispheric ACC cluster corresponds to 
270 voxels using an uncorrected significance threshold of p < 0.001 
(p = 0.072 when FWE-corrected for multiple comparisons at peak 
level; p = 0.011 when FWE-corrected for multiple comparisons at 
cluster level; MNI coordinates: x = 11, y = 29, z = 20). The left hemi-
spheric ACC cluster corresponds to 65 voxels using an uncorrected 
significance threshold of p < 0.001 (p = 0.020 when FWE-corrected 
for multiple comparisons at peak level; p = 0.114 when FWE-cor-
rected for multiple comparisons at cluster level; MNI coordinates: 
x = − 4, y = 31, z = 25)
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with pregabalin. Specific to this MRI study, we found at 
baseline that participants with hand OA demonstrated 
reduced grey matter volume in the ACC relative to non-OA 
control participants. Our study is the first, to our knowl-
edge, which reports structural brain changes in hand OA 
and supports the hypothesis of central sensitisation in hand 
OA. The evidence of structural changes in hand OA in brain 
regions associated with pain processing supports the notion 
that central pain processing is a therapeutic target in chronic 
painful conditions such as hand OA. However, this volume 
difference persisted despite a treatment induced reduction 
in clinical pain score, suggesting that the action of the treat-
ment may be affecting brain regions other than those that 
appear reduced in OA patients.
This contrasts findings from studies of hip OA, in which 
at least partial reversal of brain volumetric changes was 
observed following hip arthroplasty [5–7]. In one study, 
thalamic volume increases were noted 9 months after hip 
arthroplasty [5]. In another study, postsurgical increases in 
ACC and insula volume became evident beyond 12 weeks 
[6]. The differences in findings between our study and the 
surgical studies may reflect the different pain relief meth-
ods employed, or the better analgesic outcomes in the sur-
gical studies. They could also reflect the shorter duration 
of follow-up in our study, which might have precluded 
detection of delayed grey matter changes. Alternatively, the 
ACC changes in our cohort of hand OA participants may 
represent an irreversible maladaptive neuroplasticity of a 
chronic pain state. Longitudinal studies with longer follow-
up periods after treatment with agents such as pregabalin 
and duloxetine are required to further investigate this. Recent 
work by other groups has suggested a significant negative 
association between the ‘pain score’ component and regional 
cerebral blood flow to a right temporal lobe cluster, includ-
ing the amygdala and the parahippocampal cortex in a 
study of hand OA [15]. Tetrault et al. [16] found volumetric 
(and fMRI) changes that are associated with a reduction in 
pain for knee OA treated with placebo and duloxetine do 
not overlap within regions of grey matter that are different 
between participants with OA and non-OA controls. In their 
recent study in 39 participants with knee osteoarthritis (OA) 
patients (22 females), randomised to duloxetine (60 mg once 
daily) or placebo, Tetrault et al. [16] showed that outcomes 
for pain relief were equivalent between treatment groups. 
The group suggested that distinct circuitry changes in the 
brain could explain pain relief in each group in brain meas-
ures that included grey matter density and resting state fMRI 
nodal degree count.
It has been proposed that the ACC integrates multi-
ple facets of the pain response, including the affective, 
anticipatory and cognitive components [2, 17]. Morpho-
metric studies from several chronic pain conditions have 
identified the ACC as a focus of structural change, with 
reductions in grey matter volume frequently seen [1, 2, 6, 
7]. In functional neuroimaging studies, ACC activation is 
seen in response to painful stimuli in both healthy subjects 
and subjects with chronic pain conditions [17]. Deep brain 
stimulation of the ACC has also shown promising results 
in patients with intractable neuropathic pain [18]. Reduced 
grey matter volume in pain-regulating brain regions such 
as the ACC has been attributed to structural ‘maladaptive 
plasticity’ following chronic nociceptive input [1, 2]. The 
rostral ACC forms part of the descending inhibitory path-
way of the brain’s pain modulation network—a key com-
ponent of placebo analgesia controlled by the endogenous 
opioid system [19]. Dysregulation of this system has been 
suggested as a factor in the presence of pain in fibromy-
algic patients [20]. The anti-nociceptive effects of prega-
balin have also been shown to involve opioidergic path-
ways in animal models [21]. Our observation of reduced 
ACC grey matter volume in people with painful hand OA 
could, therefore, reflect dysregulation of the descending 
inhibitory pathway, which the actions of pregabalin and/
or duloxetine may help to resolve.
There are limitations inherent to the methodologies 
used in brain imaging as in our study, including image 
misregistration due to group differences in brain anatomy 
and motion artefact, and limitations arising from the 
small, heterogeneous patient groups included in many 
studies [14]. Our choice of a region-of-interest analytical 
approach centred on a strong a priori hypothesis, based on 
the findings of previous functional MRI studies, as well 
as morphometric studies in hip OA and other chronic pain 
conditions [1, 2, 4–7]. Although less biased, a whole-brain 
approach would have significantly less power due to the 
small number of subjects in our exploratory study and the 
large number of brain regions that would be compared. 
Confirmation of our findings in larger cohorts of patients 
could pave the way for the development of novel radio-
logical biomarkers of central sensitisation, providing clini-
cians with objective measures of which patients are likely 
to benefit from centrally acting analgesic agents.
In conclusion, our study found evidence of reduced 
ACC grey matter volume in participants with hand OA 
that persisted after treatment with centrally acting anal-
gesics pregabalin and duloxetine, respectively, despite a 
significant improvement in NRS clinical pain scores in 
the pregabalin and duloxetine groups. The ACC is a key 
pain-processing region of the brain and volume reductions 
in this brain region in hand OA participants may represent 
chronic pain-induced neural plasticity. Future longitudinal 
studies with longer follow-up periods are needed to inves-
tigate brain structural changes in chronic painful condi-
tions such as hand OA.
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